EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%

Vandana Singh

Tue, May 13, 2025, 5:00 AM 3 min read

Intelligent Bio Solutions Inc. (NASDAQ:INBS) connected Tuesday reported a 3rd 4th 2025 nonaccomplishment of 44 cents per share, down from a loss of $1.43 a twelvemonth ago.

The noninvasive investigating solutions supplier reported income of $728.87 thousand, down from $823.80 1000 a twelvemonth ago.

Total revenues accrued 20% quarter-over-quarter, supported by ongoing enlargement crossed safety-critical industries and steady lawsuit acquisition.

Also Read: EXCLUSIVE: FDA Seeks Additional Information For Intelligent Bio Solutions' Drug Screening System, Clearance Process Remains connected Track For 2025 US Launch

As we grow further into caller markets, our absorption connected increasing cartridge adoption, our highest-margin gross stream, is strengthening the concern fundamentals," said Harry Simeonidis, President and CEO astatine Intelligent Bio Solutions.

"We've besides seen a notable simplification successful losses this quarter, reflecting ongoing improvements successful outgo power and operational efficiency. To enactment planetary scalability, we introduced multilingual functionality crossed our cause screening strategy and websites, ensuring our solution is wide accessible, commercially viable, and acceptable for broader organisation crossed planetary markets. We judge these efforts are laying a beardown instauration for long-term, sustainable gross growth."

The institution secured 35 caller accounts during the 4th ended March 31, 2025, bringing its full progressive relationship basal to implicit 450.

Cartridge gross accrued from 49% to 58% for the 9 months ended March 31, 2025, an summation of 9 percent points compared to the aforesaid play successful 2024.

As of March 31, 2025, full currency and currency equivalents were $2.81 million.

Gross profits for the fiscal 3rd 4th were $341,368, an summation of 91% year-over-year.

Increases successful gross nett are chiefly attributable to enhanced accumulation capacity, which has reduced nonstop labor, nonstop materials, and nonstop product-related overhead costs.

The institution said it continues to amended its strategical income premix and operational streamlining, frankincense driving accrued gross profit.

Net nonaccomplishment attributable to the institution decreased to $2.54 cardinal from $2.98 cardinal a twelvemonth ago.

During the fiscal 3rd quarter, the institution precocious its planetary maturation strategy and merchandise readiness done a bid of targeted initiatives. These included expanded entree successful cardinal European markets, multilingual upgrades to its cause screening strategy and integer outlets, and further extortion of its halfway intelligence spot portfolio. Intelligent Bio said these developments enactment its quality to standard globally and thrust sustained commercialized growth.